[1] |
ZHANG Qi, CHEN Min, ZHANG Shiqing.
Conditional approval of medical devices in the United States and enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
|
[2] |
ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang.
Applicability of patient registry research to regulation of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427.
|
[3] |
ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing.
Advances in studies on post-market safety data sources and signal detection for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.
|
[4] |
ZHENG Yi, ZHAI Yinghong, GUO Xiaojing, XU Jinfang, CHI Lijie, GUO Zhijian, CHEN Chenxin, LIANG Jizhou, WEI Lianhui, CHEN Xiao, YE Xiaofei, HE Jia.
Thyroid immune-related adverse reactions of immune checkpoint inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 92-95.
|
[5] |
SHA Mingquan, LI Nannan, XIA Wenjing, WEI Qun, WEN Baoshu.
Research and reflection on regulatory science developments of U.S. FDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1055-1059.
|
[6] |
BAI Hehe, NIE Xiaojing, XIA Li, MA Li, WANG Jinping, PENG Lirong.
Effect evaluation of adverse drug reactions monitoring based on the Chinese hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1136-1139.
|
[7] |
TAN Jing, LIU Chunrong, HUANG Shiyao, GAO Pei, WANG Yang, LI Chen, HE Yong, YUAN Hong, WANG Wen, LI Ling, XIONG Yiquan, REN Yan, YAO Minghong, ZHAO Yan, DONG Fang, SHEN Chuanyong, SUN Xin.
Expert consensus on post-marketing risk monitoring technology for high-risk implantable passive medical devices based on real world data
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 13-17.
|
[8] |
ZHENG Chao, WU Yan, ZHANG Lan, HU Kai, ZENG Ye, WANG Wen, WANG Ling.
Methods for risk trend analysis of EU post-marketing surveillance for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 79-82.
|
[9] |
WANG Dan, REN Jingtian, WU Guizhi, XIONG Weiyi, TANG Ren, PANG Yu, FAN Rong, YANG Le.
Significance of Good Pharmacovigilance Practice in the Construction of China Pharmacovigilance System
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 501-503.
|
[10] |
JIANG Danna, LAI Wenjian, ZHAO Xiping, LIU Ying, XU Yan.
Thoughts on the Establishment of Pharmacovigilance Systems in Pharmaceutical Group Companies under Pharmacovigilance Systems
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 504-506.
|
[11] |
ZHANG Yijing.
Thoughts on How to Implement Good Pharmacovigilance Practices in China from a Global Pharmaceutical Industry Perspective
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 507-509.
|
[12] |
ZHAO Yan, ZHAO Yifei△, ZHENG Lijia, DONG Fang.
Medical Device Vigilance Systems in European Union
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 566-569.
|
[13] |
HUANG Xiankai, DONG Yinmao, MENG Hong, ZUO Min, HE Yifan, MENG Yuxi, JIA Yan.
International Cooperation on Cosmetics Regulation Promotes Regulatory Science Internationalization of Cosmetic
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 401-405.
|
[14] |
YUAN Xingdong, XU Yuming, ZHOU Juan, XU Jin, ZHONG Changming, LIU Zhijun, ZHANG Wei.
Influence of Chinese Hospital Pharmacovigilance System on Quality of ADR Reports in 2 Hospitals
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 138-140.
|
[15] |
JU Shan, LIU Yinghui, WANG Yawen, TENG Yingying, JIANG Yan, DENG Gang, SUN Lei.
Clinical Evaluation of Medical Devices Seen from International Coordination Documents
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1062-1065.
|